Roche announces new data from Phase 3 FeDeriCa trial for breast cancer
Category: #health  By Pankaj Singh  Date: 2019-12-14
  • share
  • Twitter
  • Facebook
  • LinkedIn

Roche announces new data from Phase 3 FeDeriCa trial for breast cancer

Roche Holding, a renowned Swiss healthcare company working in pharmaceuticals and diagnostics, reportedly announced novel data from its Phase 3 FeDeriCa trial. The trial showed the investigational FDC (fixed-dose combination) of pertuzumab (Perjeta®) and trastuzumab (Herceptin®), dosed by subcutaneous (SC) injection together with IV (intravenous) chemotherapy, showcased non-inferior Perjeta levels in blood (pharmacokinetics).

It also demonstrated comparable safety and efficacy to standard IV infusions of Herceptin plus Perjeta along with chemotherapy in patients suffering from HER2-positive eBC (early breast cancer).  

These novel data, from a key study analysis of the FeDeriCa trial, would be presented during a spotlight session at the 2019 SABCS (San Antonio Breast Cancer Symposium). SABCS is being held in Texas, US.

SC administration of FDC takes about eight minutes for the primary loading dose and about five minutes for every subsequent maintenance dose. This dose is compared to about 150 minutes needed for infusion of loading dose of Herceptin and Perjeta utilizing the standard IV formulations, and between 60 to 150 minutes for following maintenance infusions of two medicines.

Head of Global Product Development and Roche’s Chief Medical Officer, Levi Garraway, M.D., Ph.D. stated that this fixed-dose subcutaneous combination is capable of providing a less invasive and quicker method of administration for patients suffering from HER2-positive breast cancer, being treated with Herceptin and Perjeta.

Garraway further added that this is the first time that the company has combined two of its targeted antibodies as one subcutaneous injection which can be dosed in just minutes.

The safety profile of fixed-dose combination together with chemotherapy was comparable to IV administration of Herceptin plus Perjeta and chemotherapy. Also, no new safety signals were identified, which also includes no significant difference within cardiac toxicity. The most common adverse events found in both arms were nausea, alopecia, anemia, and diarrhea.

In earlier studies, subcutaneous administration has been shown to be highly preferred by most of the patients in comparison with IV administration of the very same medicine. The most common reason behind this was that this dosage needed less time inside the clinic.

 

Source credit: https://www.roche.com/media/releases/med-cor-2019-12-12.htm

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Pankaj Singh    

Pankaj Singh

With an experience as an insurance underwriter and a freelance writer under his belt, Pankaj Singh boasts of quite some expertise in the field of content creation. A qualified Post Graduate in Management, Pankaj has also completed a detailed course in Digital Marketin...

Read More

More News By Pankaj Singh

Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
Genentech reveals submission of sBLA to FDA for Tecentriq-Avastin
By Pankaj Singh

Genentech, Inc., a subsidiary of the Roche Group, has reportedly announced the completion of a sBLA (supplemental Biologics License Application) submission to the U.S. FDA (Food and Drug Administration) for Tecentriq ® (atezolizumab) in combinati...

FDA issues a cybersecurity warning for GE medical equipment
FDA issues a cybersecurity warning for GE medical equipment
By Pankaj Singh

The U.S. Food and Drug Administration, an agency within the U.S. Department of Health and Human Services, recently issued a safety communication informing patients, health care providers and facilities regarding the cybersecurity vulnerabilities...

French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
French-Belgian biotech PDC*LINE bags USD 22.2M in a Series B funding
By Pankaj Singh

A clinical stage biotechnology company, PDC*line Pharma, focused upon developing a new class of effective and scalable active immunotherapies for treating cancers, recently announced completion of a Series B round of funding. The company ha...